Fibroblast growth factor 21 in systemic lupus erythematosus
Part of Immune system & allergy clinical trials.
This study looks at a protein called fibroblast growth factor 21 (FGF21) in people with SLE. It aims to see if FGF21 levels are linked to lupus, which could help improve diagnosis or treatment in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of systemic lupus erythematosus (also called SLE or lupus).
- You must be at least 18 years old.
- You cannot have any other rheumatic disease, such as rheumatoid arthritis or scleroderma, or an overlap syndrome.
- You cannot have a history of cancer.
- You cannot have any liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a gene that may be linked to lupus. It aims to understand how this gene affects the disease, which could help improve future treatments.
This study tests a new investigational drug called SCTC21C for people with moderate-to-severe systemic lupus erythematosus (SLE). The goal is to see if the drug can help control lupus symptoms and reduce disease activity.
This study aims to see if a blood test that measures a specific protein-related molecule can help doctors know how active your lupus is. If successful, this could lead to a simpler way to monitor the disease and adjust treatment.
This study tests a new drug called F182112 for people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body. The drug targets certain immune cells to possibly reduce lupus symptoms.
This study looks at a protein called CXCL5 in the blood of people with lupus and whether its level relates to how active the disease is. It is a simple blood test that might help doctors understand lupus activity better.
This study looks at a blood hormone called FGF23 and whether it is linked to heart (cardiovascular) problems in people with anemia. It also compares people with anemia who do and do not have chronic kidney disease, which may help researchers understand risk and targets.
Hear when a new Systemic Lupus Erthematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.